Last reviewed · How we verify
Olmesartan medoxomil ＋Azelnidipine
This combination lowers blood pressure by blocking angiotensin II receptors (olmesartan medoxomil) and inhibiting L-type calcium channels (azelnidipine).
Olmesartan medoxomil/azelnidipine is a fixed-dose combination antihypertensive marketed in Japan by Jichi Medical University, combining an angiotensin II receptor blocker (ARB) with a calcium channel blocker (CCB). The combination leverages complementary mechanisms: olmesartan blocks AT1 receptors to reduce vasoconstriction and aldosterone secretion, while azelnidipine inhibits L-type calcium channels to promote vasodilation, providing synergistic blood pressure reduction. Approved for hypertension management, the drug has been evaluated in three Phase 4 outcome trials (COLM, OSCAR, and Japan-Combined Treatment studies) enrolling over 6,300 patients, demonstrating cardiovascular benefits in high-risk elderly populations and superiority or non-inferiority versus alternative combination strategies. The fixed-dose combination addresses polypharmacy burden in hypertension management and competes with other ARB/CCB combinations like candesartan/amlodipine. Commercial data specific to this combination is limited; the product is primarily marketed in Japan with no FDA approval. The formulation represents a rational combination approach supported by comparative efficacy data published in peer-reviewed literature.
At a glance
| Generic name | Olmesartan medoxomil ＋Azelnidipine |
|---|---|
| Also known as | arm A |
| Sponsor | Jichi Medical University |
| Drug class | Antihypertensive combination (ARB + calcium channel blocker) |
| Target | Angiotensin II type 1 receptor (AT1R) and L-type voltage-gated calcium channels |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Olmesartan medoxomil is an angiotensin II receptor blocker (ARB) that prevents vasoconstriction and reduces aldosterone secretion. Azelnidipine is a dihydropyridine calcium channel blocker that causes vasodilation by blocking calcium influx into vascular smooth muscle cells. Together, they provide complementary antihypertensive effects through different mechanisms.
Approved indications
- Hypertension
Common side effects
- Dizziness
- Headache
- Fatigue
- Hyperkalemia
- Peripheral edema
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Olmesartan medoxomil ＋Azelnidipine CI brief — competitive landscape report
- Olmesartan medoxomil ＋Azelnidipine updates RSS · CI watch RSS
- Jichi Medical University portfolio CI